Literature DB >> 3081643

Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro.

M Gowen, G R Mundy.   

Abstract

Human peripheral blood cells, when cultured in vitro, release bone-resorbing factors, which have been called osteoclast-activating factors (OAF) but remain unidentified. We showed previously that a monocyte product, similar to interleukin 1 (IL 1), is a powerful stimulator of bone resorption in vitro. However, the possibility remained that other immune cell products may contribute to OAF activity. We have therefore tested three recombinant cytokines; IL 1, interleukin 2 (IL 2), and interferon-gamma (IFN-gamma) for their activity in a neonatal mouse bone resorption assay. We report here that purified recombinant murine IL 1 is a potent and powerful stimulator of bone resorption in vitro, active over a concentration range of 0.14 to 33 U/ml (1.3 X 10(-12) to 3.1 X 10(-10) M). IL 1-stimulated bone resorption was unaffected by cyclooxygenase inhibition but was inhibited by calcitonin and IFN-gamma. IL 2 had no effect on bone resorption.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081643

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  74 in total

1.  Molecular mechanisms of the biphasic effects of interferon-γ on osteoclastogenesis.

Authors:  Jing Cheng; Jianzhong Liu; Zhenqi Shi; Joel Jules; Duorong Xu; Shaokai Luo; Shi Wei; Xu Feng
Journal:  J Interferon Cytokine Res       Date:  2011-12-05       Impact factor: 2.607

2.  Adjunctive Nd:YAG laser application in chronic periodontitis: clinical, immunological, and microbiological aspects.

Authors:  Clara Gómez; Arantza Domínguez; Ana Isabel García-Kass; Juan Antonio García-Nuñez
Journal:  Lasers Med Sci       Date:  2010-06-10       Impact factor: 3.161

3.  Is there a causal role for IL-1 in postmenopausal bone loss?

Authors:  R Pacifici
Journal:  Calcif Tissue Int       Date:  1992-04       Impact factor: 4.333

4.  Effects of recombinant human IL-1 beta on production of prostaglandin E2, leukotriene B4, NAG, and superoxide by human synovial cells and chondrocytes.

Authors:  T Tawara; M Shingu; M Nobunaga; T Naono
Journal:  Inflammation       Date:  1991-04       Impact factor: 4.092

5.  Production of an interleukin-1 inhibitor by cell line P388D1 murine macrophages stimulated with Haemophilus actinomycetemcomitans lipopolysaccharide.

Authors:  T Nishihara; T Koga; S Hamada
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

6.  Bone loss from high repetitive high force loading is prevented by ibuprofen treatment.

Authors:  N X Jain; A E Barr-Gillespie; B D Clark; D M Kietrys; C K Wade; J Litvin; S N Popoff; M F Barbe
Journal:  J Musculoskelet Neuronal Interact       Date:  2014-03       Impact factor: 2.041

7.  Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats.

Authors:  R B Kimble; J L Vannice; D C Bloedow; R C Thompson; W Hopfer; V T Kung; C Brownfield; R Pacifici
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

8.  Bone matrix constituents stimulate interleukin-1 release from human blood mononuclear cells.

Authors:  R Pacifici; A Carano; S A Santoro; L Rifas; J J Jeffrey; J D Malone; R McCracken; L V Avioli
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

Review 9.  Hypercalcaemia of malignancy.

Authors:  P J Kelly; J A Eisman
Journal:  Cancer Metastasis Rev       Date:  1989-06       Impact factor: 9.264

10.  Mouse interleukin-1 receptor antagonist induced by Actinobacillus actinomycetemcomitans lipopolysaccharide blocks the effects of interleukin-1 on bone resorption and osteoclast-like cell formation.

Authors:  T Nishihara; Y Ohsaki; N Ueda; N Saito; G R Mundy
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.